---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018788"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:18:34.450384+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enanta Q2 net loss widens to $37.7M; reports positive Phase 2 COVID-19 data, $200M royalty sale

## Summary
- Net loss $37.7M ($1.79 loss/diluted share) vs $33.6M loss ($1.63) YoY; revenue $17.8M from HCV royalties.
- Positive Phase 2 SPRINT data for EDP-235 (COVID-19): met primary endpoint; 400mg showed symptom improvement vs placebo.
- Sold 54.5% of future MAVYRET royalties to OMERS for $200M upfront; cash runway extended into calendar 2026.
- Cash and marketable securities $225.1M at March 31, 2023; plus remaining 45.5% royalty stream after cap.
- Phase 1 data for RSV L-protein inhibitor EDP-323 expected in June; dual hMPV/RSV candidate selection in Q4 2023.

## SEC filing metadata
- accession: 0000950170-23-018788
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017023018788/0000950170-23-018788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017023018788/enta-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018788
- JSON: https://secwatch.observer/filing/0000950170-23-018788.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018788.txt

## Key facts
- Earnings Releases
  ENANTA PHARMACEUTICALS INC reported fiscal second quarter ended March 31, 2023 results: revenue $17.8 million, net income net loss of $37.7 million, or a loss of $1.79 per diluted common share, EPS a loss of $1.79 per diluted common share.
  - Period: fiscal second quarter ended March 31, 2023
  - Revenue: $17.8 million
  - Net income: net loss of $37.7 million, or a loss of $1.79 per diluted common share
  - EPS: a loss of $1.79 per diluted common share
  - Result: reported results
  source text: Total revenue for the three months ended March 31, 2023 was $17.8 million and consisted of royalty revenue from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $18.7 million for the three months ended March 31, 2022. Research and development expenses totaled $43.5 million for the three months ended March 31, 2023, compared to $42.1 million for the three months ended March 31, 2022. The increase was primarily due to the timing of clinical trial expenses in our virology programs. General and administrative expenses totaled $13.8 million for the three months ended March 31, 2023, compared to $10.5 million for the three months ended March 31, 2022. The increase was due to increased stock-related compensation expense and legal fees associated with our patent infringement suit against Pfizer. Net loss for the three months ended March 31, 2023 was $37.7 million, or a loss of $1.79 per diluted common share, compared to a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017023018788/0000950170-23-018788-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.